The 2012 Third Quarterly Report of Livzon Pharmaceutical Group Inc.
The 2012 Third Quarterly Report of Livzon Pharmaceutical Group Inc.
I. Important notice
The Board of Directors (BOD), Board of Supervisors (BOS), directors, supervisors, and senior executives hereby
guarantee that the data in the present report contain no false representation, misleading statements and serious
omissions, and shall be severally and jointly liable for the authenticity, accuracy and completeness of the content.
All directors attended the shareholders’ meeting that examined this report.
Mr. Zhu Baoguo, principal of the Company, Mr. An Ning, the principal in charge of accounting, and Ms. Si Yanxia, the
principal of the Accounting Department hereby declare: We guarantee the authenticity and completeness of the Financial
Report in this quarterly report.
II. Brief introduction of the Company
(II) Financial highlights
2012.9.30 2011.12.31 Increase or decrease (%)
Total assets (RMB Yuan) 5,463,602,547.19 4,602,908,981.74 18.70%
Owners’ equity attributable
to the shareholders of listed 2,917,553,597.53 2,843,169,706.20 2.62%
company (RMB Yuan)
Share capital (Share) 295,721,852.00 295,721,852.00 0%
Net asset per share
attributable to the
9.87 9.61 2.71%
shareholders of listed
company (RMB Yuan/share)
Increase or decrease Increase or decrease
July to September compared with the January to compared with the
2012 same period of September 2012 same period of
previous year (%) previous year (%)
Total operating
1,024,017,114.12 29.23% 2,909,014,289.56 28.50%
income(RMB Yuan)
Net profit attributable to
shareholders of listed 114,925,845.48 91.57% 343,630,861.87 22.35%
company(RMB Yuan)
Net cash flows from
operating activities (RMB -- -- 529,219,276.51 29.70%
Yuan)
Net cash flows per share
from operating activities -- -- 1.79 29.71%
(RMB Yuan/share)
Basic profit per share (RMB
0.39 95% 1.16 22.11%
Yuan/share)
Diluted profit per share
0.39 95% 1.16 22.11%
(RMB Yuan/share)
Weighed yield rate of net Up 1.66 percentage po Up 1.29 percentage p
3.93% 11.93%
asset（%） ints oints
Weighed yield rate of net
assets after deduction of Up 1.05 percentage po Up 1.01 percentage
3.80% 11.41%
non-recurring profit and loss ints points
（%）
The 2012 Third Quarterly Report of Livzon Pharmaceutical Group Inc.
The items of non-recurring profit and loss (January to September 2012)
Amount from the
Items of non-recurring profit and loss year beginning to Note
end of report period
Profit and loss in disposal of non-circulation assets -2,619,231.64
Governmental allowance accrued to the current profit
and loss (except those that are closely related to the
normal operation businesses of company, comply
15,039,354.11
with the national policies, and are continuously
granted based on the certain standard quota or
certain quantity)
Except the effective hedge business related to the
normal operation business of the company, the profit
and loss in the changes of fair values caused by the
holding of tradable financial assets and tradable 6,392,098.36
financial liabilities as well as the investment returns in
disposal of tradable financial assets, tradable
financial liabilities and saleable financial assets
Other net non-operating income and payment except
529,231.20
the above items
Other profit and loss items that comply with the non-
0.
recurring profit and loss definition
Subtotal 19,341,452.03
Minus: effect of equities attributable to the minority of
3,554,087.31
shareholders
Minus: effect of income tax 761125.26
Total 15,026,239.46 --
(II) Table about total quantity of all shareholders and shareholding particulars of top ten
shareholders at the end of report period
Total quantity of
shareholders at the end of The shareholder quantity amounted to 23,004 (including 8,296 B-share holders)
report period
Shares held by top ten shareholders without trading restriction
Quantity of shares Share type and quantity
without trading
Shareholder name restriction at the
end of report Type Quantity
period
Joincare Pharmaceutical Group
77,510,167 RMB Common share 77,510,167
Industry Co., Ltd
Tiancheng Industry Co., Ltd Domestically-listed shares
50,660,052 50,660,052
for overseas investors
Domestically-listed shares
GAOLING FUND,L.P. 10,258,112 10,258,112
for overseas investors
Domestically-listed shares
First Shanghai Securities Co., Ltd 10,219,770 10,219,770
for overseas investors
Agricultural Bank of China – LOF 6,968,803 RMB Common share 6,968,803
Shenzhen Haibin Pharmaceutical Co.,
5,892,943 RMB Common share 5,892,943
Ltd
Agricultural Bank of China –Greatwall
Anxin Huibao Mixed Securities 5,700,000 RMB Common share 5,700,000
Investment Fund
Industrial and Commercial Bank of 4,783,021 RMB Common share 4,783,021
China – Jiashi Strategic Growth Mixed-t
The 2012 Third Quarterly Report of Livzon Pharmaceutical Group Inc.
ype Securities Investment Fund
Bank of Communications – Greatwall
Jiufu Core Growth Stock-type 4,725,389 RMB Common share 4,725,389
Securities Investment Fund (LOF)
Agricultural Bank of China - Invesco
Great Wall Internal Demand Growth II 4,422,792 RMB Common share 4,422,792
Stock-type Securities Investment Fund
III. Major events
(I) Great changes and reasons of main financial statement items and financial indexes of the
Company
√ Applicable □ Inapplicable
1. Items in the Balance Sheet
Items in the
Change
Balance 2012.9.30 2011.12.31 Reason
Sheet rate
Accounts The main reason is the increase of sales
742,315,684.79 562,146,013.18 32.05%
receivable incomes.
Other
The main reason is the increase of advance
accounts 59,213,582.77 44,488,052.86 33.10%
money in the sales business.
receivable
Engineering The main reason is the increase of expenses in
under 841,353,722.78 148,841,628.16 465.27% the new factory construction and technical
construction improvement.
The main reason is that the technical
Engineering improvement equipment purchased by Limin
3,543,796.60 2,536,926.00 39.69%
goods Pharmaceutical Factory has not been installed
for the time being.
The main reasons include:1) the increase of raw
Accounts materials purchased by all production
310,282,503.70 207,941,294.31 49.22%
payable enterprises;2) the increase of unsettled
engineering projects in the headquarters.
The main reason is that the difference between
Capital the equities of the minority of shareholders in
227,795,132.23 348,093,136.41 -34.56%
reserve Limin Pharmaceutical Factory and net asset
shares offset the capital reserve.
The main reason is the interests of short-term
Interests
5,538,181.90 16,841,492.68 -67.12% financing bonds of RMB 400 million Yuan that
payable
has been due.
2. The items in the Profit Statement from the year beginning to the end of report period
January to January to
Items in the Profit Change
Statement
September September Reason
2012 2011 rate
The main reason is the increase of city construction
Operating tax and 28,300,021.2
40,442,078.86 42.90% tax and education surtax that are withdrawn due to
surtax
the increase of sales incomes.
1,062,612,062.7 658,489,170. The main reason is the increase of relevant business
Sales expense 61.37%
2 63 investments due to the increase of sales incomes.
Asset depreciation 10,790,557.0 The main reason is the increase of bad debt loss
18,031,136.93 67.10%
loss 1 and depreciation loss of inventory.
Profits from the - The main reason is the increase of changes of fair
changes of fair 4,800,246.93 15,329,948.1 131.31% values of tradable financial assets held by the
values 8 company.
The main reason is the increase of investment
Investment returns 1,668,506.76 1,142,974.78 45.98%
returns from associated enterprises.
The 2012 Third Quarterly Report of Livzon Pharmaceutical Group Inc.
The main reason is the decrease of governmental
Non-operating 27,503,971.0
15,945,423.03 -42.03% allowance that is accrued to the profit and loss in this
incomes
period.
3. Items in the Cash Flow Statement
Items in the Cash January to January to Change
Flow Statement September 2012 September 2011
Reason
rate
Cash received from
2,979,324,386.9 2,229,443,047.4 The reason is the expansion of sales
sales of goods or 33.64%
4 5 business and increase of sales incomes.
rendering of services
The main reason is that the company has
increased the export rebate amount due to
Tax refunding 15,341,233.91 6,213,246.47 146.91%
the increase of product export in
Xinbeijiang Company.
The reason is the increase of governmental
financial allowance received by the group
Other cash received
as well as the research expense about
related to operating 193,038,701.95 83,981,322.58 129.86%
Shenqi and technical improvement
activities
engineering deposit received by Limin
Pharmaceutical Factory.
Other cashes paid to 1,251,391,775.8 The reason is the increase of payments
644,907,743.38 94.04%
operating activities 3 due to the expansion of sales business.
Cash paid to acquire
and construct fixed
The main reason is the increase of cashes
assets, intangible 669,948,180.40 209,089,094.21 220.41%
paid for Ningxia Industrial Park project.
assets and other long-
term assets
The main reason is that, in last
year,Dankang Company and Wenshan
Cash received from Livzon Company received the investments
- 11,270,000.00 -100.00%
investors from other shareholders, but from January
to September of this year, they have not
received any investments.
502,257,886.6 The main reason is the increase of short-
Cash from loans 172,745,504.00 190.75%
term loans of banks.
The main reason is the repayment of short-
620,250,531.1
Repayments of loans 299,293,208.34 107.24% term financing bonds of RMB 400 million
6 Yuan that has| 丽珠医药集团股份有限公司2012年第三季度报告全文（英文版） （下载公告） |
|---|
| 公告日期:2012-10-27 |
|
|
| 附件：公告原文 |
| ↑返回页顶↑ |